Linked Life Data

12043833

Source:http://linkedlifedata.com/resource/pubmed/id/12043833

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12043833rdf:typepubmed:Citationlld:pubmed
pubmed-article:12043833lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:12043833lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:12043833lifeskim:mentionsumls-concept:C1853126lld:lifeskim
pubmed-article:12043833lifeskim:mentionsumls-concept:C0525678lld:lifeskim
pubmed-article:12043833lifeskim:mentionsumls-concept:C0965251lld:lifeskim
pubmed-article:12043833lifeskim:mentionsumls-concept:C0965250lld:lifeskim
pubmed-article:12043833pubmed:issue6lld:pubmed
pubmed-article:12043833pubmed:dateCreated2002-6-4lld:pubmed
pubmed-article:12043833pubmed:abstractTextRasagiline (N-propargyl-1-(R)-aminoindan) is a selective, irreversible monoamine oxidase B (MAO B) inhibitor which has been developed as an anti-Parkinson drug. In controlled monotherapy and as adjunct to L-dopa it has shown anti-Parkinson activity. In cell culture (PC-12 and neuroblastoma SH-SY5Y cells) it exhibits neuroprotective and anti-apoptotic activity against several neurotoxins (SIN-1, MPTP, 6-hydroxydopamine and N-methyl-(R)-salsolinol) and ischemia. In vivo, it reduces the sequelae of traumatic brain injury in mice and speeds their recovery. The neuroprotective activity of rasagaline does not result from MAO B inhibition, since its S-enantiomer, TVP1022, which has 1000-fold weaker MAO inhibitory activity, exhibits similar neuroprotective properties. Introduction of a carbamate moiety into the rasagiline molecule to confer cholinesterase inhibitory activity for the treatment of Alzheimer's disease, resulted in compounds TV3326 [(N-Propargyl-(3R)Aminoindan-5-YL)-Ethyl Methyl Carbamate] and its S-enantiomer TV3279 [(N-Propargyl-(3S)Aminoindan-5-YL)-Ethyl Methyl Carbamate], which retain the neuroprotective activities of rasagiline and TVP1022. They also antagonize scopolamine-induced impairments in spatial memory. In addition, TV3326 exhibits brain-selective MAO A and B inhibitory activity after chronic administration and has antidepressant-like activity in the forced swim test. This is associated with an increase in brain levels of serotonin. The anti-apoptotic activity of these propargylamine-containing derivatives may be related to their ability to delay the opening of voltage-dependent anion channels (VDAC), which are part of the mitochondrial permeability transition pore. The propargylamine moiety is responsible for the increase in the mitochondrial family of Bcl-2 proteins, prevention in the fall in mitochondrial membrane potential, prevention of the activation of caspase 3, and of translocation of glyceraldehyde-3-phosphate dehydrogenase from the cytoplasm to the nucleus. The latter processes are closely associated with neurotoxin-induced apoptosis. Rasagiline interacts with and prevents the binding of PKI 1195 to the pro-apoptotic peripheral benzodiazepine receptor, which together with Bcl-2, hexokinase, porin, and adenine nucleotide translocator constitutes part of the VDAC. Furthermore, rasagiline, TV3326 and TV3279 are able to influence the processing of amyloid precursor protein by activation of alpha-secretase and increasing the release of soluble alpha APP in rat PC-12 and human neuroblastoma SH-SY5Y cells and in rat and mice cortex and hippocampus. This process has been shown to involve the upregulation of PKC and MAP kinase. It is quite likely that the induction of Bcl-2 and activation of PKC by rasagiline and TV3326 is closely linked to the anti-apoptotic action of these drugs and their ability to process APP by activation of alpha-secretase.lld:pubmed
pubmed-article:12043833pubmed:languageenglld:pubmed
pubmed-article:12043833pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12043833pubmed:citationSubsetIMlld:pubmed
pubmed-article:12043833pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12043833pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12043833pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12043833pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12043833pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12043833pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12043833pubmed:statusMEDLINElld:pubmed
pubmed-article:12043833pubmed:monthDeclld:pubmed
pubmed-article:12043833pubmed:issn0272-4340lld:pubmed
pubmed-article:12043833pubmed:authorpubmed-author:YoudimM BMBlld:pubmed
pubmed-article:12043833pubmed:authorpubmed-author:WeinstockMMlld:pubmed
pubmed-article:12043833pubmed:issnTypePrintlld:pubmed
pubmed-article:12043833pubmed:volume21lld:pubmed
pubmed-article:12043833pubmed:ownerNLMlld:pubmed
pubmed-article:12043833pubmed:authorsCompleteYlld:pubmed
pubmed-article:12043833pubmed:pagination555-73lld:pubmed
pubmed-article:12043833pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12043833pubmed:meshHeadingpubmed-meshheading:12043833...lld:pubmed
pubmed-article:12043833pubmed:meshHeadingpubmed-meshheading:12043833...lld:pubmed
pubmed-article:12043833pubmed:meshHeadingpubmed-meshheading:12043833...lld:pubmed
pubmed-article:12043833pubmed:meshHeadingpubmed-meshheading:12043833...lld:pubmed
pubmed-article:12043833pubmed:meshHeadingpubmed-meshheading:12043833...lld:pubmed
pubmed-article:12043833pubmed:meshHeadingpubmed-meshheading:12043833...lld:pubmed
pubmed-article:12043833pubmed:meshHeadingpubmed-meshheading:12043833...lld:pubmed
pubmed-article:12043833pubmed:meshHeadingpubmed-meshheading:12043833...lld:pubmed
pubmed-article:12043833pubmed:meshHeadingpubmed-meshheading:12043833...lld:pubmed
pubmed-article:12043833pubmed:meshHeadingpubmed-meshheading:12043833...lld:pubmed
pubmed-article:12043833pubmed:year2001lld:pubmed
pubmed-article:12043833pubmed:articleTitleMolecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].lld:pubmed
pubmed-article:12043833pubmed:affiliationEve Topf and National Parkinson Foundation Centers for Neurodegenerative Diseases Research, Department of Pharmacology, Technion-Faculty of Medicine, Haifa, Israel. youdim@tx.technion.ac.illld:pubmed
pubmed-article:12043833pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12043833pubmed:publicationTypeReviewlld:pubmed
pubmed-article:12043833pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12043833lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12043833lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12043833lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12043833lld:pubmed